Lonza Group Ltd., of Basel, Switzerland, and South San Francisco-based Denali Therapeutics Inc. announced an exclusive strategic partnership on Denali's biologic pipeline products for neurodegenerative diseases. The agreement covers all stages of the development and manufacturing, the partners said. The deal gives Denali access to Lonza's cell-line development using the GS Xceed Gene Expression System to process development and manufacturing at facilities in Slough, U.K., and Hayward, Calif.